Percent of Patients Achieving Full Dose Ramipril, Telmisartan or placebo at the end of the ONTARGET and TRANSCEND studies.
收藏数据链接：
官方服务：
资源简介：
*Risk in telmisartan/ramipril group.¶p-value (telmisartan vs. ramipril).**Risk in telmisartan/placebo group.δp-value (telmisartan vs. placebo).†p-value (asians vs. non-asians).§p for interaction.
创建时间：
2015-12-02
